Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Part I: Incidence, Clinical Course and Significance of MRI for Early Diagnosis of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Part II: Susceptibility for Aseptic Osteonecroses in Children and Adolescents With Chemotherapy for ALL or LBL

NCT01619124 is registered in ClinicalTrials.gov with Klinik für Kinder-Onkologie, -Hämatologie und Klinische Immu as lead sponsor.

NCT NCT01619124
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01619124 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Part I: Incidence, Clinical Course and Significance of MRI for Early Diagnosis of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Part II: Susceptibility for Aseptic Osteonecroses in Children and Adolescents With Chemotherapy for ALL or LBL
Lead sponsor
Klinik für Kinder-Onkologie, -Hämatologie und Klinische Immu
Phase
Observational
Overall status
Unknown status
Start date
March 31, 2012
Completion date
March 31, 2020
Enrollment
400 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukaemia, lymphoblastic lymphoma, osteonecrosis